Stuart Essig - 06 May 2025 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)

Reporting relationship: Director
Issuer ticker: IDXX
Reported as of: 06 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 May 2025, 19:00:53 UTC
Prior SEC filing: 03 Apr 2025
Next SEC filing: 13 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Lily J. Lu, Attorney-in-Fact for Stuart Essig

Key filing fact

Stuart Essig filed Form 4 for IDEXX LABORATORIES INC /DE (IDXX) on 08 May 2025.

Key facts

This page summarizes Stuart Essig's Form 4 filing for IDEXX LABORATORIES INC /DE (IDXX).
4 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 08 May 2025, 19:00.

Change

Previous filing in this sequence was filed on 03 Apr 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001187574 Primary reporting owner

ESSIG STUART

Relationship: Director
Address: ONE IDEXX DRIVE, WESTBROOK
Signature: /s/ Lily J. Lu, Attorney-in-Fact for Stuart Essig
Signature date: 08 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IDXX transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +262
Change %: +13%
Price: $0.000000
Shares after: 2,236
Date: 06 May 2025
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IDXX transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value: $0
Shares: -262
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 06 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 262
Exercise price
Footnotes: F1

IDXX transaction Derivative

Non-Qualified Stock Option (right-to-buy)

Award

Transaction value: $0
Shares: +600
Change %
Price: $0.000000
Shares after: 600
Date: 07 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 600
Exercise price: $486.61
Footnotes: F2

IDXX transaction Derivative

Deferred Stock Unit

Award

Transaction value: $0
Shares: +257
Change %
Price: $0.000000
Shares after: 257
Date: 07 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 257
Exercise price
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event was earlier.

Footnote F2

Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2026 annual meeting of shareholders, whichever event is earlier.

Footnote F3

Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2026 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.